Steven Kai Ming Lau

Steven Kai Ming Lau

Auto-generated profile, based on publicly available information

Steven Kai Ming Lau

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2009 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JDJay S Desgrosellier
Jay S Desgrosellier
LBLeo A Barnes
Leo A Barnes
DSDavid J Shields
David J Shields
MHMiller Huang
Miller Huang
SLSteven K Lau
Steven K Lau
DCDavid A Cheresh
David A Cheresh
Integrins regulate adhesion-dependent growth, survival and invasion of tumor cells. In particular, expression of integrin αvβ3 is associated with progression of a variety of human tumors. Here we reveal a previously undescribed adhesion-independent role for integrin αvβ3 in pancreatic cancer and other carcinomas. Specifically, αvβ3 expressed in carcinoma cells enhanced anchorage-independent tumor growth in vitro and increased lymph node metastases in vivo. These effects required recruitment of c-Src to the β3 integrin cytoplasmic tail, leading to c-Src activation, Crk-associated substrate (CAS) phosphorylation and tumor cell survival that, unexpectedly, was independent of cell adhesion or focal adhesion kinase (FAK) activation. Pharmacological blockade of c-Src kinase activity or decreased expression of endogenous αvβ3 integrin or c-Src not only inhibited anchorage-independent growth but also suppressed metastasis in vivo, yet these manipulations did not affect tumor cell migration or invasion. These data define an unexpected role for an integrin as a mediator of anchorage independence, suggesting that an αvβ3–c-Src signaling module may account for the aggressive behavior of integrin αvβ3–expressing tumors in humans.

6 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Yan LiuYan Liu
Yan Liu
SSStrahinja Stojadinovic
Strahinja Stojadinovic
BHBrian Hrycushko
Brian Hrycushko
ZWZabi Wardak
Zabi Wardak
SLSteven Lau
Steven Lau
XGXuejun Gu
Xuejun Gu
Accurate and automatic brain metastases target delineation is a key step for efficient and effective stereotactic radiosurgery (SRS) treatment planning. In this work, we developed a deep learning convolutional neural network (CNN) algorithm for segmenting brain metastases on contrast-enhanced T1-weighted magnetic resonance imaging (MRI) datasets. We integrated the CNN-based algorithm into an automatic brain metastases segmentation workflow and validated on both Multimodal Brain Tumor Image Segmentation challenge (BRATS) data and clinical patients' data. Validation on BRATS data yielded average DICE coefficients (DCs) of 0.75±0.07 in the tumor core and 0.81±0.04 in the enhancing tumor, which outperformed most techniques in the 2015 BRATS challenge. Segmentation results of patient cases showed an average of DCs 0.67±0.03 and achieved an area under the receiver operating characteristic curve of 0.98±0.01. The developed automatic segmentation strategy surpasses current benchmark levels and offers a promising tool for SRS treatment planning for multiple brain metastases.

12 February 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
JRJill M. Ricono
Jill M. Ricono
MHMiller Huang
Miller Huang
LBLeo A. Barnes
Leo A. Barnes
SLSteven K. Lau
Steven K. Lau
SWSara M. Weis
Sara M. Weis
DCDavid A. Cheresh
David A. Cheresh
Tyrosine kinase receptors and integrins play essential roles in tumor cell invasion and metastasis. Previously, we showed that epidermal growth factor (EGF) stimulation of pancreatic carcinoma cells led to invasion and metastasis that was blocked by antagonists of integrin αvβ5. Here, we show that EGF stimulates metastasis of carcinoma cells via a Src-dependent phosphorylation of p130 CAS leading to activation of Rap1, a small GTPase involved in integrin activation. Specifically, EGF receptor (EGFR)–induced Src activity leads to phosphorylation of a region within the CAS substrate domain, which is essential for Rap1 and αvβ5 activation. This pathway induces αvβ5-mediated invasion and metastasis in vivo yet does not influence primary tumor growth or activation of other integrins on these cells. These findings show cross-talk between a tyrosine kinase receptor and an integrin involved in carcinoma cell invasion and metastasis and may explain in part how inhibitors of EGFR affect malignant disease. [Cancer Res 2009;69(4):1383–91]

1 July 2012 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
BRBrent S. Rose
Brent S. Rose
YLYun Liang
Yun Liang
SLSteven K. Lau
Steven K. Lau
LJLindsay G. Jensen
Lindsay G. Jensen
CYCatheryn M. Yashar
Catheryn M. Yashar
LMLoren K. Mell
Loren K. Mell

1 April 2018 in Journal of Oncology Practice
Verified
Journal Article
Closed access
BGBhavani S. Gannavarapu
Bhavani S. Gannavarapu
SLSteven K.M. Lau
Steven K.M. Lau
KCKristen Carter
Kristen Carter
NCNathan A. Cannon
Nathan A. Cannon
AGAng Gao
Ang Gao
PIPuneeth Iyengar
Puneeth Iyengar
Purpose: Cancer-associated weight loss is associated with poor prognosis in advanced malignancy; however, its pretreatment prevalence and survival impact are inadequately described in large cohorts. Such data, stratified by tumor type and stage, may facilitate the optimal and timely allocation of complementary care, leading to improvements in patient survival and quality of life. Methods: We performed a retrospective cohort study of 3,180 consecutively treated adult patients with lung or GI (including colorectal, liver, and pancreatic) cancer. Pretreatment cancer-associated weight loss was based on the international consensus definition of cachexia. Prevalence and survival impact of pretreatment cancer-associated weight loss were evaluated using the Kaplan-Meier method and compared using log-rank test. Results: Cancer-associated weight loss was observed at the time of cancer diagnosis in 34.1% of patients. Pretreatment weight loss was documented in 17.6%, 25.8%, 36.6%, and 43.3% of stage I, II, III, and IV cancers, respectively. Wasting was common regardless of tumor type, with prevalence at diagnosis ranging from 27.3% in patients with colorectal cancer to 53.4% in patients with gastroesophageal cancer. Pretreatment weight loss was associated with reduced overall survival after adjusting for stage, size, grade, comorbidity, age, sex, and tobacco history (hazard ratio, 1.26; 95% CI, 1.13 to 1.39). Conclusion: Pretreatment cancer-associated weight loss is common, even in early-stage disease, and is independently associated with reduced survival. Minimal weight loss represents a clinically distinct entity with an associated overall survival intermediate to that of no weight loss and overt wasting. Early diagnosis and treatment of cancer-associated wasting offers a novel therapeutic avenue for reducing cancer mortality.

19 August 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MWMatthew J. Walter
Matthew J. Walter
JPJohn S. Park
John S. Park
RRRhonda E. Ries
Rhonda E. Ries
SLSteven K. M. Lau
Steven K. M. Lau
MMMichael McLellan
Michael McLellan
TLTimothy J. Ley
Timothy J. Ley
PU.1 is a member of the ETS family of transcription factors that is known to be important for hematopoietic development. Recently, haploinsufficiency for PU.1 has been shown to cause a shift in myelomonocytic progenitor fate toward the myeloid lineage. We have previously shown that transgenic mice expressing PML-RARα (PR) and RARα-PML frequently develop acute promyelocytic leukemia (APL) in association with a large (>20 Mb) interstitial deletion of chromosome 2 that includesPU.1. To directly assess the relevance of levels of expression ofPU.1for leukemia progression, we bred hCG-PR mice withPU.1+/-mice and assessed their phenotype. Young, nonleukemic hCG-PR ×PU.1+/-mice developed splenomegaly because of the abnormal expansion of myeloid cells in their spleens. hCG-PR ×PU.1+/-mice developed a typical APL syndrome after a long latent period, but the penetrance of disease was 84%, compared with 7% in hCG-PR ×PU.1+/+mice (P< 0.0001). The residualPU.1allele in hCG-PR ×PU.1+/-APL cells was expressed, and complete exonic resequencing revealed no detectable mutations in nine of nine samples. However, PR expression in U937 myelomonocytic cells and primary murine myeloid bone marrow cells caused a reduction inPU.1mRNA levels. Therefore, the loss of one copy ofPU.1through a deletional mechanism, plus down-regulation of the residual allele caused by PR expression, may synergize to expand the pool of myeloid progenitors that are susceptible to transformation, increasing the penetrance of APL.